HRP20100217T1 - POLIMORFI tert-BUTILNOG ESTERA ATORVASTATINA I NJIHOVA UPOTREBA KAO MEĐUPRODUKATA U DOBIVANJU ATORVASTATINA - Google Patents

POLIMORFI tert-BUTILNOG ESTERA ATORVASTATINA I NJIHOVA UPOTREBA KAO MEĐUPRODUKATA U DOBIVANJU ATORVASTATINA Download PDF

Info

Publication number
HRP20100217T1
HRP20100217T1 HR20100217T HRP20100217T HRP20100217T1 HR P20100217 T1 HRP20100217 T1 HR P20100217T1 HR 20100217 T HR20100217 T HR 20100217T HR P20100217 T HRP20100217 T HR P20100217T HR P20100217 T1 HRP20100217 T1 HR P20100217T1
Authority
HR
Croatia
Prior art keywords
atorvastatin
water
tert
butyl ester
crystalline form
Prior art date
Application number
HR20100217T
Other languages
English (en)
Croatian (hr)
Inventor
Stimac Anton
Zupet Rok
Grcman Marija
Smrkolj Matej
Jakse Renata
Original Assignee
Krka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka filed Critical Krka
Publication of HRP20100217T1 publication Critical patent/HRP20100217T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20100217T 2004-04-09 2005-04-08 POLIMORFI tert-BUTILNOG ESTERA ATORVASTATINA I NJIHOVA UPOTREBA KAO MEĐUPRODUKATA U DOBIVANJU ATORVASTATINA HRP20100217T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200400112A SI21745A (sl) 2004-04-09 2004-04-09 Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
PCT/EP2005/003733 WO2005097742A1 (en) 2004-04-09 2005-04-08 Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin

Publications (1)

Publication Number Publication Date
HRP20100217T1 true HRP20100217T1 (hr) 2010-05-31

Family

ID=34963800

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100217T HRP20100217T1 (hr) 2004-04-09 2005-04-08 POLIMORFI tert-BUTILNOG ESTERA ATORVASTATINA I NJIHOVA UPOTREBA KAO MEĐUPRODUKATA U DOBIVANJU ATORVASTATINA

Country Status (15)

Country Link
EP (1) EP1732886B1 (e)
CN (2) CN101538238B (e)
AT (1) ATE459602T1 (e)
DE (1) DE602005019703D1 (e)
DK (1) DK1732886T3 (e)
EA (1) EA010166B1 (e)
ES (1) ES2339570T3 (e)
HR (1) HRP20100217T1 (e)
NO (1) NO20065146L (e)
PL (1) PL1732886T3 (e)
PT (1) PT1732886E (e)
RS (1) RS51259B (e)
SI (2) SI21745A (e)
UA (1) UA86059C2 (e)
WO (1) WO2005097742A1 (e)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
WO2009023260A2 (en) * 2007-08-15 2009-02-19 Teva Pharmaceutical Industries Ltd. An improved process for synthesis of pyrrole derivative, an intermediate for atorvastatin
CN101560177B (zh) * 2008-04-16 2012-10-03 北京万全阳光医学技术有限公司 一种阿托伐他汀钙的制备方法
SI2413911T1 (sl) 2009-03-31 2014-04-30 Krka, D.D., Novo Mesto Progresivna emulzijska kristalizacija
CN105693587A (zh) * 2016-01-15 2016-06-22 安徽悦康凯悦制药有限公司 一种阿托伐他汀钙的生产工艺
CN109280024A (zh) * 2018-10-09 2019-01-29 河南师范大学 一种高纯度阿托伐他汀叔丁酯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
EP1341785B1 (en) * 2000-11-16 2008-10-08 Teva Pharmaceutical Industries Ltd. Hydrolysis of r(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
CN100430405C (zh) * 2001-08-16 2008-11-05 特瓦制药工业有限公司 制备他汀类的钙盐形式的方法

Also Published As

Publication number Publication date
DE602005019703D1 (de) 2010-04-15
CN101538238B (zh) 2012-08-29
UA86059C2 (ru) 2009-03-25
EA200601651A1 (ru) 2007-02-27
RS51259B (sr) 2010-12-31
ES2339570T3 (es) 2010-05-21
ATE459602T1 (de) 2010-03-15
DK1732886T3 (da) 2010-06-14
WO2005097742A1 (en) 2005-10-20
CN1946687A (zh) 2007-04-11
EA010166B1 (ru) 2008-06-30
SI1732886T1 (sl) 2010-06-30
EP1732886A1 (en) 2006-12-20
PT1732886E (pt) 2010-03-12
CN1946687B (zh) 2011-09-28
EP1732886B1 (en) 2010-03-03
CN101538238A (zh) 2009-09-23
SI21745A (sl) 2005-10-31
NO20065146L (no) 2006-11-08
PL1732886T3 (pl) 2010-08-31

Similar Documents

Publication Publication Date Title
HRP20140395T1 (hr) SPOJEVI PIROLO[2,3-d]PIRIMIDINA
ES2462065T3 (es) Proceso mejorado para la preparación de Ambrisentán e intermedios novedosos de este
JP2010539101A (ja) インテグラーゼ阻害剤の調製のためのプロセスおよび中間体
AU2006290802A1 (en) 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
CA1168244A (en) Process for 5-aroylation of 1,2-dihydro-3h- pyrrolo[1,2-a]pyrrole-1-carboxylic esters
PT1403266E (pt) Novo processo de síntese industrial do ranelato de estrôncio e dos seus hidratos
HRP20100217T1 (hr) POLIMORFI tert-BUTILNOG ESTERA ATORVASTATINA I NJIHOVA UPOTREBA KAO MEĐUPRODUKATA U DOBIVANJU ATORVASTATINA
HRP20150962T2 (hr) Postupak za pripremu atazanavir bisulfata i novih oblika
PL215879B1 (pl) Sposób syntezy przemyslowej tetraestrów kwasu 5-[bis(karboksymetylo)amino]-3-karboksymetylo-4-cyjano-2-tiofenokarboksylowego oraz zwiazek posredni 5-[bis(2-metoksy-2-oksoetylo)amino]-4-cyjano-3-(2-metoksy-2-oksoetylo)-2-tiofenokarboksylan metylu
WO2010067824A1 (ja) 光学活性カルボン酸の製造方法
CN101952245B (zh) 3-(2,2,2-三甲基肼)丙酸酯的碳酸盐和硫酸盐、及其在制备3-(2,2,2-三甲基肼)丙酸盐二水合物中的应用
CN113788766A (zh) 一种阿托伐他汀钙中间体的制备方法
JP7499259B2 (ja) αケトグルタル酸カルシウムを製造するためのプロセス
RU2019106531A (ru) Кристалл соли производного хиназолина
ES2330479T3 (es) Procedimiento para la preparacion de duloxetina.
CN102850347A (zh) 一种吡唑衍生物或其盐的拆分方法
Poulsen et al. High-pressure synthesis of enantiomerically pure C-6 substituted pyrazolo [3, 4-d] pyrimidines
CN104130146B (zh) (4s)-3，6，9-三氮杂-3，6，9-三(羧甲基)-4-(4-乙氧基苄基)十一烷二酸的制备方法
CZ2013943A3 (cs) Krystalické formy vemurafenibu
CN107935909B (zh) 一种尼达尼布（nintedanib）及其中间体的合成方法
SU1579463A3 (ru) Способ получени правовращающей 3-(3-пиридил)-1Н, 3Н-пиррол-[1,2-с]-7-тиазолкарбоновой кислоты
JP2010180173A (ja) ジメトキシナフタレン骨格を有する化合物及びその製造方法
US6861525B2 (en) Process for the preparation imidazo[1,2-A]pyridine-3-acetamides
JPH03153680A (ja) ビフェニル化合物および製造方法
CN102276576B (zh) 苯甲酰胺化合物及其制备方法